Chuanrui Xu - Search Results

Year	Number of Results
2005	1
2009	2
2010	1
2011	1
2012	4
2013	2
2014	6
2015	2
2016	1
2017	5
2018	1
2019	5
2020	7
2021	4
2022	10
2023	3
2024	1

1

β-Catenin signaling in hepatocellular carcinoma.

Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. Xu C, et al. J Clin Invest. 2022 Feb 15;132(4):e154515. doi: 10.1172/JCI154515. J Clin Invest. 2022. PMID: 35166233 Free PMC article. Review.

2

Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.

Wang T, Xu C, Zhang Z, Wu H, Li X, Zhang Y, Deng N, Dang N, Tang G, Yang X, Shi B, Li Z, Li L, Ye K. Wang T, et al. Among authors: xu c. Hepatology. 2022 Nov;76(5):1302-1317. doi: 10.1002/hep.32483. Epub 2022 Apr 24. Hepatology. 2022. PMID: 35340039 Free PMC article.

3

Bmal1 integrates mitochondrial metabolism and macrophage activation.

Alexander RK, Liou YH, Knudsen NH, Starost KA, Xu C, Hyde AL, Liu S, Jacobi D, Liao NS, Lee CH. Alexander RK, et al. Among authors: xu c. Elife. 2020 May 12;9:e54090. doi: 10.7554/eLife.54090. Elife. 2020. PMID: 32396064 Free PMC article.

4

Integrating bulk and single-cell RNA sequencing reveals cellular heterogeneity and immune infiltration in hepatocellular carcinoma.

Wang T, Dang N, Tang G, Li Z, Li X, Shi B, Xu Z, Li L, Yang X, Xu C, Ye K. Wang T, et al. Among authors: xu c. Mol Oncol. 2022 Jun;16(11):2195-2213. doi: 10.1002/1878-0261.13190. Epub 2022 Mar 1. Mol Oncol. 2022. PMID: 35124891 Free PMC article.

5

Kinsenoside attenuates liver fibro-inflammation by suppressing dendritic cells via the PI3K-AKT-FoxO1 pathway.

Xiang M, Liu T, Tian C, Ma K, Gou J, Huang R, Li S, Li Q, Xu C, Li L, Lee CH, Zhang Y. Xiang M, et al. Among authors: xu c. Pharmacol Res. 2022 Mar;177:106092. doi: 10.1016/j.phrs.2022.106092. Epub 2022 Jan 21. Pharmacol Res. 2022. PMID: 35066108 Free PMC article.

6

Coronavirus subverts ER-phagy by hijacking FAM134B and ATL3 into p62 condensates to facilitate viral replication.

Tan X, Cai K, Li J, Yuan Z, Chen R, Xiao H, Xu C, Hu B, Qin Y, Ding B. Tan X, et al. Among authors: xu c. Cell Rep. 2023 Apr 25;42(4):112286. doi: 10.1016/j.celrep.2023.112286. Epub 2023 Mar 10. Cell Rep. 2023. PMID: 36952345 Free PMC article.

7

The Role of CARD9 in Metabolic Diseases.

Tian C, Tuo YL, Lu Y, Xu CR, Xiang M. Tian C, et al. Curr Med Sci. 2020 Apr;40(2):199-205. doi: 10.1007/s11596-020-2166-4. Epub 2020 Apr 26. Curr Med Sci. 2020. PMID: 32337681 Review.

8

RNA interference as therapeutics for hepatocellular carcinoma.

Xu C, Lee SA, Chen X. Xu C, et al. Recent Pat Anticancer Drug Discov. 2011 Jan;6(1):106-15. doi: 10.2174/157489211793980097. Recent Pat Anticancer Drug Discov. 2011. PMID: 21110827 Review.

9

Targeting the IRE1α-XBP1s axis confers selective vulnerability in hepatocellular carcinoma with activated Wnt signaling.

Zhang T, Zhao F, Zhang Y, Shi JH, Cui F, Ma W, Wang K, Xu C, Zeng Q, Zhong R, Li N, Liu Y, Jin Y, Sheng X. Zhang T, et al. Among authors: xu c. Oncogene. 2024 Apr;43(17):1233-1248. doi: 10.1038/s41388-024-02988-4. Epub 2024 Feb 28. Oncogene. 2024. PMID: 38418544

10

Resveratrol Attenuates High-Fat Diet-Induced Hepatic Lipotoxicity by Upregulating Bmi-1 Expression.

Yuan W, Zhang M, Wang C, Li B, Li L, Ye F, Xu C. Yuan W, et al. Among authors: xu c. J Pharmacol Exp Ther. 2022 May;381(2):96-105. doi: 10.1124/jpet.121.001018. Epub 2022 Feb 27. J Pharmacol Exp Ther. 2022. PMID: 35221291

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

49 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year